FDA priority review raises the stakes for AstraZeneca’s Ultomiris in kidney disease

AstraZeneca is pushing deeper into rare kidney disease with Ultomiris, after the FDA granted priority review for its application in IgA nephropathy. The long-acting C5 inhibitor could offer less frequent dosing than current options if approved.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 9:20 AM ET. Details in the imprint.

AstraZeneca is moving its complement inhibitor Ultomiris deeper into kidney disease, as the US Food and Drug Administration has granted priority review for the drug’s supplemental application in immunoglobulin A nephropathy (IgAN), a chronic autoimmune condition that is a leading cause of kidney failure worldwide. The company positions Ultomiris as a long-acting C5 inhibitor with dosing every eight weeks in many patients, aiming to ease the treatment burden compared with existing complement therapies. AstraZeneca’s official press release on the IgAN filing states that the FDA has set a Prescription Drug User Fee Act (PDUFA) date in early 2025.

What AstraZeneca is targeting with Ultomiris in IgA nephropathy

IgA nephropathy is characterized by the deposition of IgA antibodies in the kidneys, leading over time to inflammation, progressive loss of kidney function and, in a substantial proportion of patients, end-stage renal disease that requires dialysis or transplantation. Current care relies mainly on supportive therapies such as optimized blood pressure control and SGLT2 inhibitors, while only a few disease-modifying drugs are approved, leaving many patients with high residual risk of progression despite guideline-directed treatment. By focusing on terminal complement component C5, Ultomiris is designed to interrupt part of the cascade implicated in glomerular inflammation and scarring in IgAN, based on both mechanistic data and early clinical findings that suggest complement activation plays a key role in disease pathology.

Ultomiris (ravulizumab) is already approved in several major markets for rare complement-mediated diseases including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), where its eight-week maintenance dosing in adults is a key differentiator versus older complement blockers requiring infusions every two weeks. Regulators and clinicians have gained years of safety and efficacy experience with the drug in these indications, which AstraZeneca hopes will support confidence as it extends the franchise into renal and neurological disorders. The company has publicly stated that the IgAN program is part of a broader strategy to expand Ultomiris into multiple complement-driven conditions, potentially increasing the number of treated patients well beyond the current ultra-rare base. In a recent analysis of the filing, investor-focused site GuruFocus noted that the FDA’s priority review designation signals the agency sees the potential for Ultomiris to provide a significant improvement over existing IgAN therapies if the pivotal data hold up under scrutiny. GuruFocus’ coverage of the priority review highlighted the possibility of an expanded rare-disease revenue pillar for AstraZeneca.

The submission for IgAN is supported by phase 3 clinical data in adults at high risk of progression, where Ultomiris was evaluated on measures including proteinuria reduction and preservation of estimated glomerular filtration rate under standard-of-care background therapy. While detailed results have not yet been fully published in peer-reviewed journals, AstraZeneca has reported that the study met its primary endpoint, with statistically significant improvements in a key surrogate marker of kidney damage compared with placebo. The priority review clock indicates that the FDA views this dataset as sufficiently robust to merit an accelerated assessment timeline, usually reducing the review period from the standard 10 months to around 6 months for a supplemental biologics license application. Industry watchers point out that, if approved, Ultomiris would enter a competitive IgAN market that already includes targeted therapies such as endothelin receptor antagonists and budesonide-based treatments, making the clinical profile and dosing advantage central to physician uptake.

From a strategic perspective, AstraZeneca is using Ultomiris to deepen its presence in immunology and rare diseases beyond its oncology-heavy portfolio, adding potential multi-indication biologics that can support long-term revenue growth. The long-acting C5 inhibitor originated from Alexion, which AstraZeneca acquired in 2021 to gain a foothold in complement biology and established rare disease franchises, and it now forms one of the core biologic platforms the group is scaling across therapeutic areas. In Australia and Europe, specialist media have in parallel reported on AstraZeneca’s pipeline of cardiovascular, renal and metabolic candidates as it targets up to $80 billion in total revenue by 2030, with complement drugs seen as a meaningful contributor among high-value niche products. A recent Pharma in Focus report on AstraZeneca’s portfolio ambitions underscored how late-stage assets in hypertension and renal disease are being positioned alongside biologics like Ultomiris in investor expectations.

Within AstraZeneca’s broader pipeline, potential approval of Ultomiris in IgA nephropathy would reinforce the company’s diversification beyond oncology and respiratory drugs, adding another specialty indication where it can leverage existing infusion infrastructure and rare-disease commercialization expertise. Shares of AstraZeneca (ISIN GB0009895292) traded on the NASDAQ under the ticker AZN closed at $79.24 on 06/13/2026, reflecting how investors are already factoring in expectations around the company’s expanding late-stage portfolio.

Ultomiris in IgA nephropathy: key facts at a glance

• Product: Ultomiris (ravulizumab) for IgA nephropathy
• Manufacturer: AstraZeneca PLC
• Category: New Release / Launch (supplemental biologics license application)
• Launch date: Pending FDA decision following priority review (PDUFA in early 2025)
• MSRP / Price: Not yet set for IgA nephropathy; pricing established for existing indications may inform future positioning
• Availability: Already marketed for PNH and aHUS in major markets; IgA nephropathy indication under FDA priority review
• Target audience: Adults with immunoglobulin A nephropathy at high risk of kidney disease progression despite standard of care
• Key differentiator / USP: Long-acting C5 complement inhibition with maintenance dosing every eight weeks in many patients, potentially reducing infusion frequency versus existing complement inhibitors

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.